The Conversation (0)
Vital Therapies Inc, a company that develops bio-artificial liver needed to treat life-threatening acute liver failure, has announced that it has increased its multi-stage financing to $100 million.
Vital Therapies Inc, a company that develops bio-artificial liver needed to treat life-threatening acute liver failure, has announced that it has increased its multi-stage financing to $100 million.
As quoted in the press release:
Since the initial closing in September 2012, more than $30 million has been invested under the multi-stage financing, with up to approximately $70 million remaining to be funded at future scheduled closings. The next closing is scheduled for July, which would bring the total amount invested under the multi-stage financing to more than $50 million.
Click here to read the full Vital Therapies Inc press release.
